PureTech Health plc (PRTC)
NASDAQ: PRTC · Real-Time Price · USD
16.77
-0.14 (-0.83%)
Dec 15, 2025, 4:00 PM EST - Market closed
PureTech Health Employees
PureTech Health had 56 employees as of December 31, 2024. The number of employees decreased by 34 or -37.78% compared to the previous year.
Employees
56
Change (1Y)
-34
Growth (1Y)
-37.78%
Revenue / Employee
$114,125
Profits / Employee
$904,964
Market Cap
395.23M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 56 | -34 | -37.78% |
| Dec 31, 2023 | 90 | -21 | -18.92% |
| Dec 31, 2022 | 111 | 16 | 16.84% |
| Dec 31, 2021 | 95 | -155 | -62.00% |
| Dec 31, 2020 | 250 | -50 | -16.67% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PRTC News
- 7 days ago - PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis - Business Wire
- 10 days ago - PureTech's Founded Entity Gallop Oncology Announces Positive Initial Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome - Business Wire
- 7 weeks ago - PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with Idiopathic Pulmonary Fibrosis (IPF), a Historically Undertreated Group - Business Wire
- 2 months ago - PureTech Presents New Data from Phase 2b Open-Label Extension Study of Deupirfenidone (LYT-100), Further Supporting Strong and Durable Efficacy and Potential to Serve as New Standard of Care in IPF - Business Wire
- 3 months ago - PureTech Health plc (PRTC) Q2 2025 Earnings Conference Call Transcript - Seeking Alpha
- 3 months ago - PureTech Health plc – Half-Year Report - Business Wire
- 4 months ago - PureTech Showcases Differentiated Development Strategy, Including New Patient Preference Insights, and Spotlights Phase 2b Data Positioning Deupirfenidone as a Potential New Standard of Care in IPF - Business Wire
- 4 months ago - PureTech Health: Notice of Half-Yearly Results - Business Wire